MAIA Biotechnology Files 8-K: Material Agreement & Equity Sales
Ticker: MAIA · Form: 8-K · Filed: Mar 13, 2024 · CIK: 1878313
| Field | Detail |
|---|---|
| Company | Maia Biotechnology, INC. (MAIA) |
| Form Type | 8-K |
| Filed Date | Mar 13, 2024 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 5 min |
| Key Dollar Amounts | $0.0001, $1.17, $2.4 million, $1, $529,695 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, equity-sale, financials
Related Tickers: MAIA
TL;DR
MAIA Bio inked a big deal, sold some stock, and filed financials. Keep an eye on this one.
AI Summary
MAIA Biotechnology, Inc. announced on March 11, 2024, that it entered into a material definitive agreement. The company also reported on unregistered sales of equity securities and filed financial statements and exhibits. The filing details are for MAIA Biotechnology, Inc., incorporated in Delaware, with its principal executive offices in Chicago, IL.
Why It Matters
This 8-K filing indicates significant corporate activity for MAIA Biotechnology, including a new material agreement and equity transactions, which could impact its financial standing and future operations.
Risk Assessment
Risk Level: medium — The filing involves material definitive agreements and unregistered sales of equity, which can introduce financial and operational risks.
Key Numbers
- 001-41455 — SEC File Number (Identifies the company's filing with the SEC.)
- 83-1495913 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- MAIA Biotechnology, Inc. (company) — Registrant
- March 11, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- Chicago, IL (location) — Address of principal executive offices
FAQ
What is the nature of the material definitive agreement entered into by MAIA Biotechnology, Inc.?
The filing does not specify the details of the material definitive agreement, only that one was entered into on or before March 11, 2024.
What type of equity securities were sold in the unregistered sale?
The filing mentions unregistered sales of equity securities but does not provide specific details about the type or amount of securities sold.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on March 11, 2024.
Where are MAIA Biotechnology, Inc.'s principal executive offices located?
MAIA Biotechnology, Inc.'s principal executive offices are located at 444 West Lake Street, Suite 1700, Chicago, IL 60606.
What are the main items reported in this 8-K filing?
This 8-K filing reports on the entry into a material definitive agreement, unregistered sales of equity securities, and financial statements and exhibits.
Filing Stats: 1,227 words · 5 min read · ~4 pages · Grade level 13.1 · Accepted 2024-03-13 17:14:00
Key Financial Figures
- $0.0001 — f the Company's common stock, par value $0.0001 per share (" Common Stock "), and (ii)
- $1.17 — s Common Stock, at a price per share of $1.17 for an aggregate purchase price of appr
- $2.4 million — gregate purchase price of approximately $2.4 million. The Shares and the Warrants (and the
- $1 — are exercisable at a price per Share of $1.30, which price represents the greater
- $529,695 — gregate purchase price of approximately $529,695 The Director Warrants are exercisable a
- $1.30 — Warrants are exercisable at a price of $1.30 per share, which price represents the g
- $2.92 m — ferings is expected to be approximately $2.92 million, prior to deducting offering expe
Filing Documents
- d778616d8k.htm (8-K) — 31KB
- d778616dex101.htm (EX-10.1) — 325KB
- 0001193125-24-066954.txt ( ) — 574KB
- maia-20240311.xsd (EX-101.SCH) — 3KB
- maia-20240311_lab.xml (EX-101.LAB) — 18KB
- maia-20240311_pre.xml (EX-101.PRE) — 11KB
- d778616d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: March 13, 2024 MAIA BIOTECHNOLOGY, INC. By: /s/ Vlad Vitoc Name: Vlad Vitoc Title: Chief Executive Officer 4